Longpre Lara's Form 4 filing
Mirum Pharmaceuticals, Inc. (MIRM) · filed Mar 18, 2024
- Accession no.
- 0001415889-24-008316
- Filed
- Mar 18, 2024
- Trade date
- Sep 10, 2019-Jan 9, 2023
- Filing delay
- 1,651 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $10.3K. Open-market sales total $20.7K. It was filed 1651 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Longpre LaraCIK 0001780347 | Officer (CHIEF DEVELOPMENT OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2019 | Common Stock | PPurchaseAcquired | +965 | $10.64F1 | +$10,267.6 | 105,372 | Direct | |
| Jan 9, 2023 | Common Stock | SSaleDisposed | −1,003 | $20.62 | −$20,681.86 | 104,369 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The weighted average purchase price for the transaction reported was $10.64, and the range of prices were between $10.20 and $10.8799. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
Referenced by the price of 1 transaction in Table I.